Clinical Research Article

Hipopara-Red, Real Life Experience in 322 Patients With Hypoparathyroidism

María Belén Zanchetta,1,2 Damián Robbiani,1,2 Beatriz Oliveri,3 Evangelina Giaconia,4 Adriana Frigeri,5 Silvia Kallsbrum,6 Helena Salerni,6 Sabrina Lucas,7 Adriana Díaz,7 Betiana Perez,8 Luisina Pieroni,5 María Auxiliadora Arce Lange,5 Silvina Torno,4 Ariela Kitaigrodsky,8 and Ana María Galich8

1IDIM, Instituto de Investigaciones Metabólicas, C1012 Buenos Aires, Argentina; 2Facultad de Medicina, Cátedra de Osteología, Universidad del Salvador, C1055 Buenos Aires, Argentina; 3Mautalen, Salud e Investigación, C1128 Buenos Aires, Argentina; 4Servicio de Endocrinología y Metabolismo, Hospital Posadas, B1684 Provincia de Buenos Aires, Argentina; 5Unidad de Endocrinología, Hospital Dr T. Alvarez, C1406 Buenos Aires, Argentina; 6Servicio de Endocrinología, Hospital Carlos G Durand, C1405 Buenos Aires, Argentina; 7Sección Osteopatías Médicas, División Endocrinología de Clínicas José de San Martín-UBA, C1120 Buenos Aires, Argentina; and 8Servicio de Endocrinología, Hospital Italiano de Buenos Aires, C1199 Buenos Aires, Argentina

ORCID number: 0000-0002-9397-1847 (Z. María Belén).

Received: 24 June 2020; Editorial Decision: 11 November 2020; First Published Online: 28 November 2020; Corrected and Typeset: 31 December 2020.

Abstract

Context: Hypoparathyroidism is a rare disease and, as such, its natural history, long-term complications, and correct clinical management remain unclear.

Objective: To describe the natural history and clinical characteristics of the disease.

Design and Setting: To present a retrospective observational analysis from 7 specialized centers in Buenos Aires, Argentina.

Patients: Chronic hypoparathyroid patients followed-up between 1985 and December 2018.

Main Outcome Measures: Data on demographics, etiology, clinical complications, biochemical parameters, dual-energy x-ray absorptiometry (DXA) values, and treatment doses were collected.

Results: A total of 322 subjects with chronic hypoparathyroidism were included; 85.7% were female, the mean age was 55.2 ± 16.8 years, and the mean age at diagnosis was 43.8 ± 16.8 years. Prevalence of surgical hypoparathyroidism was 90.7%, with the most common causes being thyroid carcinoma and benign thyroid disease. A history of hypocalcemia requiring hospitalization was present in 25.7% of the whole group and in 4.3% of patients who had a history of seizures. Overall, 40.9% of our patients had reported at least 1 neuromuscular symptom. Renal insufficiency was present in 22.4% of our patients and was significantly associated with age (P < 0.0001). Hyperphosphatemia was present in 42% of patients. A history of severe hypocalcemia, paresthesias, tetany, ganglia calcifications, seizures, and cataracts was significantly higher in nonsurgical patients.
Hypoparathyroidism is a rare disorder characterized by hypocalcemia and hyperphosphatemia due to absent or inadequate parathyroid hormone (PTH) secretion [1]. The unintentional surgical damage of the parathyroid glands is the most common form, occurring in approximately 78% of cases [1]. Definitive postsurgical hypoparathyroidism is diagnosed when PTH production is insufficient to maintain normocalcemia 6 months after the intervention [2]. Overall, the incidence of chronic hypoparathyroidism after neck surgery is <2%, depending on the surgeon’s expertise [3]. Nonsurgical hypoparathyroidism is attributable to autoimmune, genetic, or idiopathic etiologies, which typically become manifest in childhood [1]. The estimated prevalence varies between 23 to 30 per million inhabitants in nonsurgical hypoparathyroidism and 220 to 250 per million inhabitants in surgical hypoparathyroidism [4–6].

As it is a rare disease, data on quality of life, long-term risk of complications, and correct clinical management have just started to emerge. What is best known is the spectrum of neuromuscular symptoms related to hypocalcemia: mainly paresthesia, cramps, or tetany, but also seizures, bronchospasms, laryngospasm, or cardiac rhythm disturbances [1]. Fewer data are available regarding consequences in the renal, ophthalmic, cardiovascular systems, fracture risk, infections, and psychiatric conditions. The real prevalence of these complications is not available because systematic screening is scarce worldwide [7].

Consequently, recent management guidelines stress the importance of a better clinical assessment of these patients [7]. In addition to the routine biochemical monitoring of serum levels of calcium, phosphate, and magnesium, some guidelines recommend wider screening, as clinically indicated, including annual estimated glomerular filtration rate, renal imaging and 24-hour urinary calcium excretion. These screenings would be aimed at assessing renal insufficiency nephrocalcinosis and nephrolithiasis. Central nervous system imaging would evaluate basal ganglia calcifications, and ophthalmologic exams and a frequent quality of life assessment should also be included in the screening [2–7].

Inadequate PTH secretion causes failure to mobilize calcium from bone, reabsorb it from the distal nephron, and stimulate renal 1α-hydroxylase activity, leading to hypocalcemia. Therapeutic tools include calcium and vitamin D supplements, active vitamin D (1,25(OH) vitamin D or calcitriol), analogues that require liver activation (1α-hydroxyvitamin D: alfacalcidol and dihydrotachysterol), and thiazide diuretics [2]. Higher calcium requirements may cause hypercalciuria, and higher calcitriol doses increase the risk of hyperphosphatemia, so a delicate equilibrium is essential. Therefore, although there is little evidence available regarding how to best treat hypoparathyroidism, the current general goals of management are: maintaining serum calcium levels in the lower part or slightly below the lower limit of the reference range, keeping serum phosphate and magnesium levels and 24-hour urinary calcium excretion within range, and keeping the calcium-phosphate product below 55 mg²/dl² [2, 7–9]. A major challenge in hypoparathyroidism patients continues to be the effective therapeutic management of the disease in order to minimize the adverse effects of a lifelong treatment.

In 2015, replacement therapy with rhPTH 1–84 was first approved in the United States as a useful therapeutic option for hypoparathyroidism, and it was restricted to those patients who are difficult to manage with conventional therapy [10]. A group of experts recommend considering its use based on these clinical criteria: inadequate control of the serum calcium concentration, very high oral calcium/vitamin D requirements (>2.5 g of calcium or >1.5 ug of active vitamin D or >3 ug of the 1-α vitamin D analog), hypercalciuria, kidney stones, nephrocalcinosis or reduced creatinine clearance, hyperphosphatemia and/or calcium-phosphate product that exceeds 55 mg²/dl², gastrointestinal tract disorder with malabsorption, and reduced quality of life [2].

This context of unmet needs and knowledge gaps motivated us to analyze and share our experience treating patients with this rare disease. Our primary endpoint was to describe the natural history and clinical characteristics of a group of patients with hypoparathyroidism from 7 referral bone centers in Argentina. The secondary endpoint was to describe differences between surgical and nonsurgical hypoparathyroid (HP) patients and our third endpoint, to analyze the number of patients on inadequate control who would meet experts’ indications for considering the use of rhPTH 1–84.

**Conclusion:** Although these patients were followed-up by experienced physicians, clinical management was heterogeneous and probably insufficient to assess all the potential complications of this chronic disease. Almost 70% of the study’s group of patients met the experts’ indications for considering the use of rhPTH 1–84. Being aware of this fact is the 1st step in improving our medical management of this disease in the future.

**Key Words:** hypoparathyroidism, PTH, hypocalcemia, hyperphosphatemia
Materials and Methods

Patients

A retrospective observational analysis of chronic hypoparathyroidism patients from 7 specialized centers (Hipopara-Red) from Buenos Aires, Argentina, was carried out. To be included, subjects should have had a concurrent measurement of albumin-corrected or ionized serum calcium below the lower limits of the normal range and low or undetectable levels of PTH on at least 2 occasions separated by 2 weeks. A duration of hypocalcemia ≥6 months was considered for inclusion criteria in surgical hypoparathyroidism. Patients with pseudohypoparathyroidism were excluded. Each center collected requested data from all patients, fulfilling the inclusion criteria from their historic database, and its analysis was carried out by a centralized institution. Data of demographics, age at diagnosis, disease duration (period between diagnosis and the last visit), and etiology were recorded. Clinical manifestations or complications were registered regarding hypocalcemia requiring hospitalization, neuromuscular manifestations (paresthesias, tetany, muscle spasms, or pain and seizures), kidney ultrasound-positive findings (stones or nephrocalcinosis), renal insufficiency (defined by creatinine clearance <60 ml/minute), basal ganglia calcification, detailed fragility fracture history, and cataracts. All the above clinical manifestations or complications were considered positive and were included in the analysis, if present at least once during follow-up. The most recent biochemical parameters available in medical records included serum calcium (mg/dl), ionized calcium (mg/dl), serum phosphorus (mg/dl), calcium–phosphate product (mg²/dl²), PTH (pg/ml), serum 25-hydroxyvitamin D (ng/ml), 24-hour urine calcium, and serum magnesium (mg/dl). In most patients, baseline parameters were not available for analysis. The most recent dual-energy x-ray absorptiometry (DXA) values and treatment regimens (type and doses) were also collected. According to the World Health Organization criteria, osteoporosis was defined as a bone mineral density (BMD) that lies 2.5 standard deviations (SDs) or more below the average value for young, healthy women (a T-score of <-2.5 SD). In women prior to menopause and in males younger than age 50, a Z-score of -2.0 or lower was defined as osteopenia [11].

Differences between surgical and nonsurgical hypoparathyroidism regarding demographics, clinical manifestations, biochemical parameters, DXA values, and treatment were analyzed.

The study was conducted according to the Helsinki Declaration and was approved by the local ethics committee. Each participant was identified by a number to ensure confidentiality.

Data Analysis

Data were expressed as mean ± SD and the Shapiro-Wilk and Bartlett tests were used to assess normality and equal variances, respectively. The Student’s t-test or Mann-Whitney test was used as appropriate to compare surgical and nonsurgical groups. Differences were considered significant if P < 0.05. Statistical analyses were performed with STATISTIX 7.0 analytical software (Statsoft, Oklahoma, USA). The association between each complication and possible associated factors was evaluated using univariate logistic regression. The contingency tables were analyzed using the Fisher’s test.

Results

Demographics

A total of 322 subjects with chronic hypoparathyroidism were included, 276 (85.7%) were female and 46 (14.3%) male (female/male ratio: 6:1). The mean age at the last visit was 55.2 ± 16.8 years; only 3 subjects were younger than 18 years of age (0.9%). The mean age at diagnosis was 43.8 ± 16.8 years; disease duration (median time between diagnosis and last visit) was 10.9 ± 9.9 years (Table 1). This database included all subjects followed-up between 1985 and December 2018 in Buenos Aires, Argentina. The last follow-up visit date ranged from December 2002 to November 2018.

Etiology

The majority of patients had surgical hypoparathyroidism (90.7%, n = 292; 258 were female and 34 were male) mainly due to thyroid carcinoma (45.6%), benign thyroid adenoma (37.3%), parathyroidectomy (5.6%), and other neck surgeries (2.2%). Benign thyroid adenoma implied benign thyroid disease, including single adenoma, goiter, multinodular goiter, or Graves’ disease. Nonsurgical hypoparathyroidism represented the remaining 9.3% patients (n = 30, 18 female and 12 male): idiopathic (5%), autoimmune (2.8%) and Di George (1.5%). See Fig. 1.

In a subanalysis of patients who had undergone thyroid surgery of benign and malignant etiologies, we noticed a significant trend over the years. Before 2010, 49.6% of our patients became hypoparathyroid following a surgery to remove a benign thyroid adenoma. After 2010, hypoparathyroidism secondary to surgery for benign thyroid disease went down to 37.2% (P = 0.0330).

Clinical Manifestations and Complications

Paresthesias were found in 31.3% of our patients, tetany in 14.2% of our patients, muscle spasms in 13.3% of them, and muscle pain in 6.8% of our patients; 40.9% of them reported at least 1 neuromuscular symptom.

A history of hypocalcemia requiring hospitalization was present in 25.7% of our patients (n = 83) and
14 patients (4.3%) had a history of seizures. These 2 events were related, with seizures being significantly associated with hospitalization for hypocalcemia ($P = 0.017$). Also, seizures were positively associated with hyperphosphatemia, elevated calcium–phosphate product, and higher doses of calcium supplementation ($P = 0.019$, 0.020, and <0.0001, respectively). Basal ganglia calcifications were present in 5/14 patients with a history of seizures, although only 8/14 had been screened using central nervous system imaging (Table 1). Out of all the participants (n = 322), basal ganglia calcifications were present in 23 patients. Although it is worth noting that the screening rate was very low, only 59/322 patients had had undergone nervous system image screening.

Patients with basal ganglia calcifications without seizures did not have any other neurological problems, at least not reported in this database, except for paresthesias, muscle spasms, or tetany, which as a whole, were present in 83.3% of our patients.

Kidney assessment by renal ultrasound was performed in 41.9% (135/322) patients and 15.5% (21/135) had positive findings (kidney stones [n = 15] and nephrocalcinosis [n = 6]). Creatinine clearance calculation was available in 277 patients and was below the normal range (<60 ml/minute/1.73m$^2$) in 62 patients (22.4%). Renal insufficiency was significantly associated with age ($P < 0.0001$): 2/50 (4%) in patients younger than 39; 17/106 (16%) in patients between 40 and 59 years of age; 25/95 (26.3%) in patients between 60 and 79; and 18/26 (69.2%) in patients older than 80. Patients older than 60 years of age had a 2.9-fold more risk than those younger than 60 to have creatinine clearance below 60 ml/minute (odds ratio, 2.918; 95% confidence interval, 1.617–5.263).

Regarding fracture history, only nontraumatic fractures were included and were present in 4.9% of our group: a total of 17 fractures (4 hip, 1 fibula, 2 humerus, 1 rib, 3 vertebrae, and 6 wrists) in 14 patients, mean age 71.2 years, range 23 to 94 years. All fractured patients were female, except for a 23-year old male with Di George syndrome diagnosed with celiac disease after a bilateral hip fracture. Apart from this young man, the other youngest patient was a 50-year-old woman with a history of hyperparathyroidism and premature ovarian failure who fractured her wrist. All the other patients

---

**Table 1. Demographic data and clinical characteristics of the whole group and surgical and nonsurgical subgroups**

| Demographics | All (n = 322) | Surgical (n = 292) | Nonsurgical (n = 30) | P-value |
|--------------|--------------|-------------------|---------------------|---------|
| Age (years)  | 54.3 ± 16.8  | 55.4 ± 16.1       | 43.3 ± 18.9         | 0.0003  |
| Female       | 276 (85.7 %) | 258 (88.3 %)      | 18 (60 %)           | 0.0002  |
| Age at diagnosis | 43.8 ± 16.8 | 45 ± 15.9         | 31.4 ± 20.5         | <0.01  |
| Disease duration (years) | 10.9 ± 9.9 | 10.7 ± 10        | 12.5 ± 9.5          | 0.25   |

**Clinical Manifestations (%)**

| Severe hypocalcemia | 83 (25.7) | 68 (23.2) | 15 (50) | 0.003* |
| Paresthesias        | 101 (31.3) | 84 (28.7) | 17 (56.6) | 0.003* |
| Tetany              | 46 (14.2) | 35 (12) | 11 (36.6) | 0.001* |
| Muscle spasms       | 43 (13.3) | 35 (12) | 8 (26.6) | 0.042* |
| Muscle pain         | 22 (6.8) | 19 (6.5) | 3 (10) | 0.444* |
| Seizures            | 14 (4.3) | 7 (2.3) | 7 (23.3) | <0.0001* |
| eGFR < 60 [n (%)]   | 62 (22.4) | 58 (23) | 4 (16) | 0.42* |
| Lithiasis/nephrocalcinosis | 21/135 (15.5) | 19/117 (16.2) | 2/18 (11.1) | 0.738* |
| Basal ganglia calcification | 23/59 (38.9) | 14/46 (30.4) | 9/13 (69.2) | 0.021* |
| Fracture history    | 14 (4.3) | 11 (3.8) | 3 (10) | 0.131* |
| Cataracts           | 11 (3.4) | 8 (2.7) | 3 (10) | 0.072* |

*Two-sample proportion test. Severe hypocalcemia is defined as hypocalcemia requiring hospitalization.

**Figure 1.** Etiology in 322 patients with hypoparathyroidism. Thyroid adenoma implies benign thyroid disease, including single adenoma, goiter, multinodular goiter, or Graves’ disease.

---

**Chronic hypoparathyroidism etiology**

- Thyroid carcinoma
- Thyroid adenoma
- Parathyroidectomy
- Other neck surgery
- Idiopathic
- Autoimmune
- Di George

| Percentage (%) | Surgical | Non-surgical |
|----------------|----------|--------------|

---

**Abbreviation: eGFR, estimated Glomerular filtration rate.**

The etiology of chronic hypoparathyroidism in 322 patients included various conditions, with thyroid adenoma being the most common.
with a fracture were older than 60 years. In regard to hypoparathyroidism etiology, 11/14 patients (78.5%) were postsurgical, 1 had Di George syndrome, and 2 were idiopathic. Disease duration ranged between 7 and 44 years. Vertebral fractures (N = 3) were clinical and confirmed by X-ray, associated with osteopenia or osteoporosis, and present in patients older than 80 years.

Only 3.4% (n = 11) of patients reported a history of cataracts, with a mean age of 64 ± 19.5 (22–87 years), and with a mean disease duration of 20.2 ± 11.9 years (5–38 years). Mean phosphorus level was 4.7 ± 0.8 mg/dL (upper limit of the normal range). In this group, 8/11 patients had a surgical etiology (mean age 78) and 3 nonsurgical (mean age 43). The youngest woman with cataracts was 22 years old, had a 5-year autoimmune hypoparathyroidism, hyperphosphatemia, basal ganglia calcifications, and a history of multiple hospitalizations for hypocalcemia.

Biochemical Parameters

Data for serum calcium were available in 99.3% of our patients and the mean calcium level was 8.4 ± 0.8 mg/dL; 46% were below the lower limit, 53.6% were within the normal range, and only 1 patient had hypercalcemia (Table 2). Plasma phosphate values were available in 95.4% of our patients; only 1 patient was below the lower limit, 57.3% were within the normal range, and 42.1% were above the normal range. Elevated calcium–phosphate product (>55 mg²/dL²) was present in 1.2% of our patients. Mean serum PTH levels were low (13.4 ± 10.8 pg/ml) and clearly inadequate for serum calcium values. Serum 25-hydroxyvitamin D levels were available in 46% of our patients: 50.7% were higher than 30 ng/ml, 30.4% were between 20 and 30 ng/ml, and 19.9% were under 20 ng/ml. Urinary 24-hour calcium excretion was available in 58.4% of our patients, and 49.4% of those screened had values above the gender reference range.

Serum magnesium levels were available in 80.1% of our patients (n = 247) and were lower than the reference range in 24.3% of patients. Only 1 patient had values above the normal range. The rest (75%) were within the reference range but in the medium or lower tertile of the normal range. Remarkably, half of the patients with serum magnesium levels in the lower tertile were receiving supplements.

DXA Values

Lumbar spine and hip DXA assessment was performed in 123/322 (38%) of the patients. The mean lumbar spine T-score was -0.3 ± 1.9, the mean femoral neck T-score was -0.3 ± 1.5, and the mean total hip T-score was -0.2 ± 1.3. There were no significant differences in T-score or Z-score.

### Table 2. Biochemical parameters and treatment characteristics of the whole group and surgical and nonsurgical subgroups

| Biochemical Parameters (Normal Range) | All (n = 322) | Surgical (n = 292) | Nonsurgical (n = 30) | P-value |
|--------------------------------------|--------------|--------------------|----------------------|---------|
| Calcium (8.5–10.5 mg/dl)             | 8.4 ± 0.8    | 8.4 ± 0.8          | 8.4 ± 0.9            | 0.51    |
| Ionized calcium (4.1–5.2 mg/dl)      | 4.2 ± 0.5    | 4.3 ± 0.5          | 4.1 ± 0.6            | 0.17    |
| Albumin (3.2–4.8 g/l)                | 4.1 ± 0.4    | 4.1 ± 0.4          | 4.3 ± 0.4            | 0.14    |
| Phosphorus (2.5–5 mg/dl)             | 4.7 ± 0.9    | 4.7 ± 0.9          | 4.9 ± 1.0            | 0.12    |
| PTH (10–65 pg/ml)                    | 13.4 ± 10.8  | 13.5 ± 10.9        | 11.7 ± 9.6           | 0.47    |
| 25-hydroxyvitamin D (30 ng/ml)       | 34.9 ± 13.2  | 34.3 ± 13.1        | 42.6 ± 13.5          | 0.029   |
| Magnesium (1.9–2.5 mg/dl)            | 1.9 ± 0.2    | 1.9 ± 0.2          | 1.9 ± 0.2            | 0.66    |
| Urine calcium (220 mg/24hr)          | 201.5 ± 131.9| 198.5 ± 134.4      | 228.2 ± 105.6        | 0.16    |
| Hypercalcuria (%)                    | 98/174 (56.3)| 87/156 (55.7)      | 11/18 (61.1)         | 0.803   |
| Creatinine (0.6–1.1 mg/dl)           | 0.93 ± 0.54  | 0.93 ± 0.54        | 0.94 ± 0.52          | 0.88    |
| eGFR (≥60 ml/min/1.73m²)             | 76.0 ± 24.8  | 74.8 ± 23.5        | 88.2 ± 34.2          | 0.07    |
| **Treatment (doses)**                |              |                    |                      |         |
| Calcium (mg/day)                     | 2019 ± 1426  | 2033 ± 1447        | 1876 ± 1232          | 0.67    |
| Calcitriol (ug/day)                  | 0.498 ± 0.279| 0.491 ± 0.275      | 0.566 ± 0.321        | 0.26    |
| Magnesium (mg/day)                   | 328 ± 368    | 316 ± 366          | 415 ± 381            | 0.23    |
| Thiazides (mg/day)                   | 30.8 ± 21.4  | 32.7 ± 22.0        | 16.2 ± 5.9           | 0.17    |
| Vitamin D (thousand IU/week)         | 28.1 ± 22    | 27.6 ± 22          | 33.3 ± 26            | 0.37    |

Abbreviations: eGFR, estimated glomerular filtration rate; hr, hour; min, minute; PTH, parathormone; SD, standard deviation.

*Unequal variances.

*Nonparametric distribution.

Two-sample proportion test. We provide T- and Z-scores for all patients (n = 123), although T-score (< -2.5 SD) was used in postmenopausal women and men older than 50, and Z-score was used in women prior to menopause and in males younger than age 50 (< -2.0) to define osteoporosis or low bone mass, respectively. Vitamin D was both ergo or cholecalciferol. Patients receiving rhPTH 1–84 or rhPTH 1–34 (n = 14) were excluded from the biochemical analysis in this table.
values between postsurgical and nonsurgical patients (data not shown). Although mean values were within the normal range, 48/123 (39%) patients had osteopenia and 16/123 (13%) had osteoporosis.

**Treatment**

The decision on treatment election was made by the patient’s endocrinologist. Most patients were receiving calcium supplements (mean dose $2019 \pm 1426$ mg/day, expressed as elemental calcium) plus calcitriol (mean dose $0.498 \pm 0.279$ ug/day) and 22.9% were receiving diuretics (hydrochlorothiazide [16%), indapamide [3.7%]) (Table 2). More than half (54.3%) the patients were receiving vitamin D supplementation.

Fourteen patients (4.3%) were receiving PTH supplementation (13 female and 1 male); median age was 49.57 (18–88 years) and median time since diagnosis was 9 years. Thirty patients received rhPTH 1–34 and 1 patient received rhPTH 1–84. These patients had a history of frequent intravenous calcium administration and episodes of life-threatening severe hypocalcemia. Thirteen patients were postsurgical and 1 was idiopathic. Most were still requiring calcium supplements (1792 mg/day) and calcitriol (0.51 ug/day). It is important to clarify that these off-label rhPTH 1–34 treatments were started before rhPTH 1–84 was available and approved for hypoparathyroidism.

**Differences Between Surgical and Nonsurgical HP Patients**

Nonsurgical hypoparathyroidism subjects were younger and were diagnosed at a younger age, and the female:male ratio was more balanced (60% were women) (Table 1). A history of severe hypocalcemia, paresthesias, tetany, and muscle spasms were significantly more frequent in nonsurgical patients. Ganglia calcifications, seizures, and cataracts were significantly higher. There were no differences regarding renal complications, biochemical parameters, DXA values, or treatment characteristics (Tables 1 and 2).

**Candidates Who Met Experts’ Indications for Considering the Use of rhPTH 1–84**

According to the international guidelines, 210 of our patients met experts’ indications for considering the use of rhPTH 1–84. If we add the 14 that were already receiving it, the number rises to 69.5% (n = 224) of our group of patients [2] (Table 3). According to the experts recommendations, hyperphosphatemia would be the indication to consider rhPTH 1–84 for the majority of our patients, daily oral calcium requirements exceeding 2.5 g of calcium would be for 74 patients, and only one woman because she was taking $>1.5 \mu$g of active vitamin D. Inadequate control of the serum calcium concentration was the reason why 14 patients were already under treatment with rhPTH 1–34 or rhPTH 1–84. In the remaining cases, the patients presented with hypercalcemia, kidney stones, nephrocalcinosis, or reduced estimated glomerular filtration rate (eGFR). (See the detailed numbers in Table 3). Quality of life was not evaluated, so it could not be used as indication criterion (or it could not be considered within the indication criteria).

**Discussion**

In this observational retrospective cross-sectional study, we described the natural history of 322 subjects with hypoparathyroidism. We found a higher prevalence of postsurgical etiology (90.7%) compared with the prevalence described in the literature (67–78 %) [1, 2, 6]. This

| Indications for Considering the Use of rhPTH 1–84 in our patients [2] | Number of Patients |
|---------------------------------------------------------------|---------------------|
| Inadequate control of the plasma calcium concentration         | 14 (4.34%)          |
| Oral calcium that exceeds 2.5 g of calcium                     | 74 (22.9%)          |
| ≥1.5 ug of calcitriol                                          | 1 (0.3%)            |
| Hypercalcemia                                                  | 98 (30.43%)         |
| Kidney stones                                                  | 15 (4.65%)          |
| Nephrocalcinosis                                               | 6 (1.86%)           |
| Reduced clearance (≤60 mL/min)                                 | 62 (19.25%)         |
| Hyperphosphatemia and/or calcium-phosphate product exceeding 55 mg$^2$/dL$^2$ (4.4 mmol$^2$/L$^2$) | 124 (38.55)         |
| Total patients (several fulfilled ≥1 criteria)                | 224 (69.5%)         |

Several patients fulfilled more than one of the criteria. The 14 patients already with rhPTH 1–84 or rh PTH 1–34 were the ones with inadequate control of the plasma calcium concentration.

*Abbreviation: min, minute.*
could be attributed to the fact that our centers mainly treat adults, so we do not usually see pediatric patients who might have contributed with more nonacquired etiology.

Most of our patients were premenopausal women, whose diagnosis was made after a thyroid surgery, which is consistent with the prevalence of thyroid nodular disease. Regrettably, almost 40% of our patients suffered this lifelong condition after surgery for a benign thyroid disease. The extents of the surgery, central compartment node dissection, and reoperation have been described as risk factors for developing hypoparathyroidism [12]. We had no data on the type of surgical procedure but, fortunately, after 2010 we observed a significant decrease in the number of patients becoming hypoparathyroid after surgery for benign thyroid disease.

The history of severe hypocalcemia requiring hospitalization was present in 1/4 of our patients; and less severe hypocalcemia was responsible for at least 1 neuromuscular symptom, this being reported in 40% of our patients. The prevalence of seizures was similar to that described in the literature (4–8%), and it was clearly more prevalent in nonsurgical patients [3].

Concern has been raised regarding renal impairment as a higher risk of kidney stones, nephrocalcinosis, renal insufficiency, and even dialysis [4]. Kidney stones or nephrocalcinosis were found only in 15.5% of our group, probably because less than half of our patients had had a renal ultrasound performed. A high prevalence of nephrocalcinosis (12–57%) and a hazard ratio for developing kidney stones of 4.82 (95% CI, 2.00–11.64) was reported in patients with hypoparathyroidism who were treated with calcium and activated vitamin D [4, 13]. Renal insufficiency, defined by creatinine clearance below 60 ml/minute, was present in 22.4% of our patients and it was significantly associated with age, ranging from 4% in those who were younger than 39 years old to 69.2% in patients older than 80. This prevalence is higher than expected for our general population; in a study done on 88,500 blood and urine samples in Buenos Aires, the authors reported a prevalence of 12% of our patients [14]. Impaired renal function has been associated with age, duration of the disease, and relative time with hypercalcemia [15]. Two-thirds of subjects included in an early intervention trial had decreased creatinine clearance values at baseline, and 40% had verified renal calcinosis [16]. In a US cohort, 41% of patients had an eGFR <60 ml/minute/1.73m², which was between 2- and 17-fold higher than the age-adjusted normal values [15]. In 2 Danish case-control studies, the hazard ratios for renal insufficiency were 3 (95% CI, 1.73–5.55) and 6 (95% CI, 2.45–14.75) for patients with surgical and nonsurgical hypoparathyroidism, respectively, compared with age-matched controls [4, 17].

Data on fracture risk among patients with this disorder vary. In some postsurgical hypoparathyroid cohorts, patients may have a decreased risk of fracture in the upper extremities, whereas others show an increased risk of vertebral fractures despite having normal or increased bone mineral density [18–21]. Nontraumatic fractures were present in 5% of our group and almost all had happened in aged postmenopausal women. Although there are no published data on the general incidence of fragility fractures in our country, prevalence of asymptomatic vertebral fractures in Argentinian women aged 50 was estimated in 16.19% in the Latin American Vertebral Osteoporosis Study (LAVOS) study [22].

In our group, 42% had serum phosphate levels above the reference range. Underbjerg et al recommended that serum phosphate in this population should be kept in the lower part of the reference interval, because higher phosphate levels are associated with increased mortality and risk of infections [17]. Unfortunately, in our patients, lowering serum phosphate seems to be one of the most challenging tasks.

In Argentina, we tend to favor calcium over active vitamin D use: mean calcium elemental requirements were around 2000 mg/day and calcitriol at 0.5 ug/day. This perspective is similar to the US experience but different from the European experience, which focuses more on the 1-alpha analogue of vitamin D than on supplemental calcium. Fourteen patients were receiving PTH supplementation: 13 with rhPTH 1–34 and 1 with rhPTH 1–84. These patients had previously had more frequent hospitalizations, more severe hypocalcemia, higher serum phosphate and calcium urinary excretions, and higher calcium and calcitriol requirements than a control group of patients receiving standard treatment [23]. With PTH supplementation, their serum calcium levels improved and calcium and calcitriol requirements decreased and became similar to those of the conventionally treated group.

As expected and previously reported, nonsurgical hypoparathyroidism subjects were younger and had been diagnosed at an earlier age; besides, the number of female patients was lower [5, 24]. Overall, they seem to have more complications, especially those related to hypocalcemia such as neuromuscular symptoms, cataracts, basal ganglia calcifications, and seizures [5]. Underbjerg et al found that these patients had a significantly increased risk of renal insufficiency (HR 6.01), cardiovascular diseases (HR 1.91), neuropsychiatric complications (HR 2.45), infections (HR 1.94), and fractures at the upper extremities compared with a control group [5].

According to the experts’ indications, 210 of our patients might be eligible for the use of rhPTH, although it is not yet commercially available in Argentina [2]. However,
these indications are not strict evidence-based recommendations but rather guidance to consider treatment with rhPTH 1–84. We were surprised and worried about the high percentage of patients with inadequate control, especially patients with hyperphosphatemia and renal complications. This high number might partially be explained by the significant percentage of patients older than 60 years of age and even older than 80 with renal insufficiency.

We are aware that due to the retrospective design of our study, the prevalence of acute and chronic complications is probably underdiagnosed in our patients. Less than half of our patients met the screening recommendations for renal ultrasound, 24-hour urine calcium excretion, and central nervous system imaging assessment, which probably underestimated the prevalence of basal ganglia calcifications, nephrocalcinosis, hypercalciuria, and kidney stones. Also, we only recorded self-reported cataracts. We were not able to evaluate quality of life, fatigue, lack of concentration, depression, and other neuropsychiatric issues. Other limitations of this study are that the participating centers were almost exclusively for adults, which exaggerates surgical etiology, and the lack of genetic testing for the diagnosis of nonsurgical cases. Moreover, all centers were from the capital city, Buenos Aires, and it is uncertain whether these data can be extrapolated to the whole Argentinian population. Patients in our cohort were evaluated at reference centers and thus, they might have been more severely affected with a higher rate of complications than the overall population (referral bias). Finally, the results of laboratory values over a time span and from different facilities might be affected by changes in assay technology and performance.

That being said, our results were generally consistent with peer-reviewed reports. The main strengths of this study are the large number of patients included, the long follow-up period, and the complete biochemical profile. In addition, according to our knowledge, this is the first study on hypoparathyroidism in Argentina and Latin America.

As a conclusion, analyzing our experience, we have learned several lessons. Despite being followed-up by experienced physicians, clinical management and monitoring were heterogeneous and probably insufficient to assess all the potential complications. Hyperphosphatemia was present in a high proportion of our patients and more than half might have been eligible to receive treatment with rhPTH 1–84. Being aware of our current management of this rare disease is the first step to improving our clinical approach in the future. Longitudinal prospective studies including the whole country are necessary to permit a better understanding of the clinical manifestations, short- and long-term complications, and therapeutic challenges of these patients.

Acknowledgments

We want to thank Lucas Brun and Fernando Silveira for the statistical analysis and Magdalena Pavlove for contributing with her patients. Also, Susan Carballo for assistance in editing the manuscript.

Additional Information

Correspondence: María B. Zanchetta, MD, Libertad 836, C1012 Buenos Aires, Argentina. E-mail: mzbanchetta@idim.com.ar.

Disclosure Summary: M.B.Z. had received speaker honoraria from Shire/Takeda, Ultragenyx, and Amgen. A.M.G. had received speaker honoraria from Shire/Takeda. E.G. had received speaker honoraria from Takeda, Ultragenyx, and Rafto. B.O. had received speaker honoraria from Shire/Takeda. H.S. had received speaker honoraria from Amgen. The others authors declare that they have no conflict of interest concerning this paper. This study was done independently for Takeda and received no financial support to conduct it; the author report no conflicts of interest. The author has submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Conflicts that the editors consider relevant to the content of the manuscript have been disclosed.

Data Availability: Some or all data generated or analyzed during this study are included in this published article or in the data repositories listed in References.

References and Notes

1. Gafni RI, Collins MT. Hypoparathyroidism. N Engl J Med. 2019;380(18):1738–1747.
2. Brandi ML, Bilezikian JP, Shoback D, et al. Management of hypoparathyroidism: summary statement and guidelines. J Clin Endocrinol Metab. 2016;101(6):2273–2283.
3. Bilezikian JP. Hypoparathyroidism. J Clin Endocrinol Metab. 2020;105(6):1722–1736.
4. Underbjerg L, Sikjaer T, Mosekilde L, Rejmark L. Cardiovascular and renal complications to postsurgical hypoparathyroidism: a Danish nationwide controlled historic follow-up study. J Bone Miner Res. 2013;28(11):2277–2285.
5. Underbjerg L, Sikjaer T, Mosekilde L, Rejmark L. The epidemiology of nonsurgical hypoparathyroidism in Denmark: a nationwide case finding study. J Bone Miner Res. 2015;30(9):1738–1744.
6. Powers J, Joy K, Ruscio A, Lagast H. Prevalence and incidence of hypoparathyroidism in the United States using a large claims database. J Bone Miner Res. 2013;28(12):2570–2576.
7. Bollerslev J, Rejmark L, Marconcì C, et al; European Society of Endocrinology. European Society of Endocrinology clinical guideline: treatment of chronic hypoparathyroidism in adults. Eur J Endocrinol. 2015;173(2):G1–20.
8. Maeda SS, Moreira CA, Borba VZC, et al. Diagnosis and treatment of hypoparathyroidism: a position statement from the Brazilian society of endocrinology and metabolism. Arch Endocrinol Metab. 2018;62(1):106–124.
9. Khan AA, Koch CA, Van Uum S, et al. Standards of care for hypoparathyroidism in adults: a Canadian and international consensus. Eur J Endocrinol. 2019;180(3):P1–P22.
10. Food and Drug Administration. FDA-Approved Drugs. ProMED-mail website. https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=125511. Published 2015. Accessed November 6, 2020.

11. Shuhart CR, Yeap SS, Anderson PA, et al. Executive summary of the 2019 ISCD position development conference on monitoring treatment, DXA cross-calibration and least significant change, spinal cord injury, peri-prosthetic and orthopedic bone health, transgender medicine, and pediatrics. J Clin Densitom. 2019;22(4):453–471.

12. Lorente-Poch L, Sancho JJ, Muñoz-Nova JL, Sánchez-Velázquez P, Sitges-Serra A. Defining the syndromes of parathyroid failure after total thyroidectomy. Gland Surg. 2015;4(1):82–90.

13. Mannstadt M, Bilezikian JP, Thakker RV, et al. Hypoparathyroidism. Nat Rev Dis Prim. 2017;3(1):17055.

14. Inserra F, Cornelio C, Daverio S, Diehl S, Samarelli N, Diaz A. Frecuencias relativas de diabetes creatininas elevadas y proteinuria en análisis clínicos de Buenos Aires. Rev Nefrol Dial Traspl. 2017;33(4):233–48.

15. Mitchell DM, Regan S, Cooley MR, et al. Long-term follow-up of patients with hypoparathyroidism. J Clin Endocrinol Metab. 2012;97(12):4507–4514.

16. Winer KK, Ko CW, Reynolds JC, et al. Long-term treatment of hypoparathyroidism: a randomized controlled study comparing parathyroid hormone-(1-34) versus calcitriol and calcium. J Clin Endocrinol Metab. 2003;88(9):4214–4220.

17. Underbjerg L, Sikjaer T, Rejnmark L. Long-term complications in patients with hypoparathyroidism evaluated by biochemical findings: a case-control study. J Bone Miner Res. 2018;33(5):822–831.

18. Underbjerg L, Sikjaer T, Mosekilde L, Rejnmark L. Postsurgical hypoparathyroidism–risk of fractures, psychiatric diseases, cancer, cataract, and infections. J Bone Miner Res. 2014;29(11):2504–2510.

19. Underbjerg L, Malmstroem S, Sikjaer T, Rejnmark L. Bone status among patients with nonsurgical hypoparathyroidism, autosomal dominant hypocalcaemia, and pseudohypoparathyroidism: a cohort study. J Bone Miner Res. 2018;33(3):467–477.

20. Mendonça ML, Pereira FA, Nogueira-Barbosa MH, et al. Increased vertebral morphometric fracture in patients with postsurgical hypoparathyroidism despite normal bone mineral density. BMC Endocr Disord. 2013;13:1.

21. Chawla H, Saha S, Kandasamy D, Sharma R, Sreenivas V, Goswami R. Vertebral fractures and bone mineral density in patients with idiopathic hypoparathyroidism on long-term follow-up. J Clin Endocrinol Metab. 2017;102(1):251–258.

22. Clark P, Cons-Molina F, Deleze M, et al. The prevalence of radiographic vertebral fractures in Latin American countries: the Latin American vertebral osteoporosis study (LAVOS). Osteoporos Int. 2009;20(2):275–282.

23. Kitaigrodsky AV, Diehl M, Galich AM, et al. Tratamiento prolongado con teriparatide en el hipoparatiroidismo grave de difícil manejo. Actual Ostel. 2015;11(2):114–124.

24. Astor MC, Lovás K, Debowska A, et al. Epidemiology and health-related quality of life in hypoparathyroidism in Norway. J Clin Endocrinol Metab. 2016;101(8):3045–3053.